Development of a Novel Rapid Sepsis Point of Care Diagnostic Device

新型快速败血症护理诊断设备的开发

• 批准号: 10017144
• 金额: $ 38.42万
• 依托单位: FREQUASENSE LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2022
• 资助国家: 英国
• 起止时间: 2022 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=10017144
• 关键词: Development; Novel; Rapid; Sepsis; Point

More than 350,000 people suffer from sepsis in the UK annually, leading to 52,000 deaths. Rapid diagnosis is imperative to enable timely administration of interventional antibiotic treatment, however current methods are insufficient to empower clinicians to act within the critical first hour of admission. Early antibiotic therapy is vital to clinical outcomes, with the risk of septic-shock patient mortality increasing by 7.6% with a delay of every 1 hour in antibiotic administration. As recognised by the UK Government and World Health Organisation objectives, there is an urgent unmet clinical need to develop a simple, rapid and accurate test for sepsis, to facilitate fast intervention for patients with bacterial sepsis. Our technology measures levels of the sepsis-specific CRP-VLDL complex biomarker within a handheld, near-patient point-of-care rapid diagnostic, which seamlessly incorporates into the current clinical care pathway.

在英国，每年有超过35万人患有败血症，导致5.2万人死亡。快速诊断是必要的，以便能够及时给予介入抗生素治疗，然而，目前的方法不足以使临床医生在入院后关键的第一个小时内采取行动。早期抗生素治疗对临床结果至关重要，每延迟1小时抗生素给药，败血症休克患者死亡风险增加7.6%。正如英国政府和世界卫生组织的目标所认识到的那样，开发一种简单、快速和准确的脓毒症检测方法，以促进对细菌性脓毒症患者的快速干预，是一个迫切的未满足的临床需求。我们的技术测量败血症特异性CRP-VLDL复杂生物标志物的水平，在手持式，近病人护理点快速诊断，无缝整合到当前的临床护理途径。